49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 946 薬物数 : 733 - (DrugBank : 186) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 198

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00189124
(ClinicalTrials.gov)
September 200313/9/2005Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) PreventionDoes DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?Systemic Lupus ErythematosusDrug: Dehydroepiandrosterone (DHEA)University of MichiganArthritis FoundationCompleted18 YearsN/AFemale13Phase 2/Phase 3United States
2NCT00082511
(ClinicalTrials.gov)
July 200311/5/2004GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsA Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsSystemic Lupus ErythematosusDrug: Prasterone (GL701)Genelabs TechnologiesNULLCompleted18 YearsN/AFemale114Phase 3United States;Mexico
3NCT00053560
(ClinicalTrials.gov)
December 200230/1/2003To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With GlucocorticoidsA Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsLupusDrug: Prasterone (GL701)Genelabs TechnologiesNULLActive, not recruiting18 YearsN/AFemale155Phase 3United States;Mexico
4NCT00391924
(ClinicalTrials.gov)
May 200024/10/2006Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's SyndromeFatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone AdministrationLupus Erythematosus, Systemic;Sjogren's SyndromeDrug: DehydroepiandrosteroneUMC UtrechtUniversity Medical Centre Groningen;Dutch Arthritis AssociationCompleted18 YearsN/AFemale120Phase 2Netherlands
5NCT00004662
(ClinicalTrials.gov)
March 199624/2/2000Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: dehydroepiandrosteroneNational Center for Research Resources (NCRR)Northwestern UniversityCompleted18 YearsN/AFemale300Phase 3NULL
6NCT00004665
(ClinicalTrials.gov)
June 199524/2/2000Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: dehydroepiandrosteroneNational Center for Research Resources (NCRR)Northwestern UniversityCompleted18 YearsN/AFemale20Phase 2NULL
7NCT00004795
(ClinicalTrials.gov)
August 199424/2/2000Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: dehydroepiandrosteroneNational Center for Research Resources (NCRR)Northwestern UniversityCompleted18 YearsN/AFemale190Phase 2/Phase 3NULL